Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients

Olga G. Kulakova, Ekaterina Yu Tsareva, Alexey N. Boyko, Sergey G. Shchur, Evgeny I. Gusev, Dmitrijs Lvovs, Alexander Favorov, Koen Vandenbroeck, Olga O. Favorova

Research output: Contribution to journalArticle

Abstract

Background: IFN-β is widely used as the first-line disease-modifying treatment for multiple sclerosis. However, 30-50% of multiple sclerosis patients do not respond to this therapy. Identification of genetic variants and their combinations that predict responsiveness to IFN-β could be useful for treatment prognosis. Materials & methods: The combinations of alleles of nine polymorphic loci in immune-response genes were analyzed in 253 Russian multiple sclerosis patients as possible determinants of clinically optimal IFN-β treatment response using APSampler software. Results: Carriage of TGFB1*-509C and CCR5*d was associated with favorable IFN-β response by itself. CCR5*d, IFNAR1*16725G, IFNG*874T and IFNB1*153T/T were the components of the combinations, associated with clinically optimal response to IFN-β. Carriage of composite markers (CCR5*d + IFNAR1*G + IFNB1*T/T) or (CCR5*d + IFNAR1*G + IFNG*T) is beneficial for IFN-β treatment efficacy. Discussion: The data obtained provides evidence of the cumulative effect of immune-response genes on IFN-β treatment efficacy. This joint contribution may reflect the additive effect of independent allelic variants and epistatic interactions between some of them. Original submitted 2 July 2012; Revision submitted 21 September 201.

Original languageEnglish (US)
Pages (from-to)1689-1700
Number of pages12
JournalPharmacogenomics
Volume13
Issue number15
DOIs
StatePublished - Nov 2012

Fingerprint

Multiple Sclerosis
Genes
Therapeutics
Software
Alleles

Keywords

  • APSampler
  • biomarker
  • composite marker
  • epistasis
  • IFN-β
  • interferon-β
  • multiple sclerosis
  • pharmacogenomics
  • polymorphism
  • SNP

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Kulakova, O. G., Tsareva, E. Y., Boyko, A. N., Shchur, S. G., Gusev, E. I., Lvovs, D., ... Favorova, O. O. (2012). Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients. Pharmacogenomics, 13(15), 1689-1700. https://doi.org/10.2217/pgs.12.161

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients. / Kulakova, Olga G.; Tsareva, Ekaterina Yu; Boyko, Alexey N.; Shchur, Sergey G.; Gusev, Evgeny I.; Lvovs, Dmitrijs; Favorov, Alexander; Vandenbroeck, Koen; Favorova, Olga O.

In: Pharmacogenomics, Vol. 13, No. 15, 11.2012, p. 1689-1700.

Research output: Contribution to journalArticle

Kulakova, OG, Tsareva, EY, Boyko, AN, Shchur, SG, Gusev, EI, Lvovs, D, Favorov, A, Vandenbroeck, K & Favorova, OO 2012, 'Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients', Pharmacogenomics, vol. 13, no. 15, pp. 1689-1700. https://doi.org/10.2217/pgs.12.161
Kulakova, Olga G. ; Tsareva, Ekaterina Yu ; Boyko, Alexey N. ; Shchur, Sergey G. ; Gusev, Evgeny I. ; Lvovs, Dmitrijs ; Favorov, Alexander ; Vandenbroeck, Koen ; Favorova, Olga O. / Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients. In: Pharmacogenomics. 2012 ; Vol. 13, No. 15. pp. 1689-1700.
@article{632ad8040e124d569d543767ef6267bf,
title = "Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients",
abstract = "Background: IFN-β is widely used as the first-line disease-modifying treatment for multiple sclerosis. However, 30-50{\%} of multiple sclerosis patients do not respond to this therapy. Identification of genetic variants and their combinations that predict responsiveness to IFN-β could be useful for treatment prognosis. Materials & methods: The combinations of alleles of nine polymorphic loci in immune-response genes were analyzed in 253 Russian multiple sclerosis patients as possible determinants of clinically optimal IFN-β treatment response using APSampler software. Results: Carriage of TGFB1*-509C and CCR5*d was associated with favorable IFN-β response by itself. CCR5*d, IFNAR1*16725G, IFNG*874T and IFNB1*153T/T were the components of the combinations, associated with clinically optimal response to IFN-β. Carriage of composite markers (CCR5*d + IFNAR1*G + IFNB1*T/T) or (CCR5*d + IFNAR1*G + IFNG*T) is beneficial for IFN-β treatment efficacy. Discussion: The data obtained provides evidence of the cumulative effect of immune-response genes on IFN-β treatment efficacy. This joint contribution may reflect the additive effect of independent allelic variants and epistatic interactions between some of them. Original submitted 2 July 2012; Revision submitted 21 September 201.",
keywords = "APSampler, biomarker, composite marker, epistasis, IFN-β, interferon-β, multiple sclerosis, pharmacogenomics, polymorphism, SNP",
author = "Kulakova, {Olga G.} and Tsareva, {Ekaterina Yu} and Boyko, {Alexey N.} and Shchur, {Sergey G.} and Gusev, {Evgeny I.} and Dmitrijs Lvovs and Alexander Favorov and Koen Vandenbroeck and Favorova, {Olga O.}",
year = "2012",
month = "11",
doi = "10.2217/pgs.12.161",
language = "English (US)",
volume = "13",
pages = "1689--1700",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients

AU - Kulakova, Olga G.

AU - Tsareva, Ekaterina Yu

AU - Boyko, Alexey N.

AU - Shchur, Sergey G.

AU - Gusev, Evgeny I.

AU - Lvovs, Dmitrijs

AU - Favorov, Alexander

AU - Vandenbroeck, Koen

AU - Favorova, Olga O.

PY - 2012/11

Y1 - 2012/11

N2 - Background: IFN-β is widely used as the first-line disease-modifying treatment for multiple sclerosis. However, 30-50% of multiple sclerosis patients do not respond to this therapy. Identification of genetic variants and their combinations that predict responsiveness to IFN-β could be useful for treatment prognosis. Materials & methods: The combinations of alleles of nine polymorphic loci in immune-response genes were analyzed in 253 Russian multiple sclerosis patients as possible determinants of clinically optimal IFN-β treatment response using APSampler software. Results: Carriage of TGFB1*-509C and CCR5*d was associated with favorable IFN-β response by itself. CCR5*d, IFNAR1*16725G, IFNG*874T and IFNB1*153T/T were the components of the combinations, associated with clinically optimal response to IFN-β. Carriage of composite markers (CCR5*d + IFNAR1*G + IFNB1*T/T) or (CCR5*d + IFNAR1*G + IFNG*T) is beneficial for IFN-β treatment efficacy. Discussion: The data obtained provides evidence of the cumulative effect of immune-response genes on IFN-β treatment efficacy. This joint contribution may reflect the additive effect of independent allelic variants and epistatic interactions between some of them. Original submitted 2 July 2012; Revision submitted 21 September 201.

AB - Background: IFN-β is widely used as the first-line disease-modifying treatment for multiple sclerosis. However, 30-50% of multiple sclerosis patients do not respond to this therapy. Identification of genetic variants and their combinations that predict responsiveness to IFN-β could be useful for treatment prognosis. Materials & methods: The combinations of alleles of nine polymorphic loci in immune-response genes were analyzed in 253 Russian multiple sclerosis patients as possible determinants of clinically optimal IFN-β treatment response using APSampler software. Results: Carriage of TGFB1*-509C and CCR5*d was associated with favorable IFN-β response by itself. CCR5*d, IFNAR1*16725G, IFNG*874T and IFNB1*153T/T were the components of the combinations, associated with clinically optimal response to IFN-β. Carriage of composite markers (CCR5*d + IFNAR1*G + IFNB1*T/T) or (CCR5*d + IFNAR1*G + IFNG*T) is beneficial for IFN-β treatment efficacy. Discussion: The data obtained provides evidence of the cumulative effect of immune-response genes on IFN-β treatment efficacy. This joint contribution may reflect the additive effect of independent allelic variants and epistatic interactions between some of them. Original submitted 2 July 2012; Revision submitted 21 September 201.

KW - APSampler

KW - biomarker

KW - composite marker

KW - epistasis

KW - IFN-β

KW - interferon-β

KW - multiple sclerosis

KW - pharmacogenomics

KW - polymorphism

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=84870034810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870034810&partnerID=8YFLogxK

U2 - 10.2217/pgs.12.161

DO - 10.2217/pgs.12.161

M3 - Article

VL - 13

SP - 1689

EP - 1700

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 15

ER -